Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

被引:525
作者
Unger, Roger H. [1 ,2 ]
Cherrington, Alan D. [3 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA
[2] VA N Texas Hlth Care Syst, Dallas, TX USA
[3] Vanderbilt Univ, Sch Med, Dept Physiol & Biophys, Nashville, TN 37212 USA
关键词
HEPATIC GLUCOSE-PRODUCTION; AMYLIN ANALOG PRAMLINTIDE; A-CELL FUNCTION; ALPHA-CELL; RECEPTOR ANTAGONIST; PANCREATIC GLUCAGON; VENTROMEDIAL HYPOTHALAMUS; METABOLIC SYNDROME; LEPTIN THERAPY; PLASMA-GLUCOSE;
D O I
10.1172/JCI60016
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total beta cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive beta cells normally regulate juxtaposed alpha cells and that without intraislet insulin, unregulated alpha cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 96 条
[11]   IMMUNONEUTRALIZATION OF ENDOGENOUS GLUCAGON WITH MONOCLONAL GLUCAGON ANTIBODY NORMALIZES HYPERGLYCEMIA IN MODERATELY STREPTOZOTOCIN-DIABETIC RATS [J].
BRAND, CL ;
ROLIN, B ;
JORGENSEN, PN ;
SVENDSEN, I ;
KRISTENSEN, JS ;
HOLST, JJ .
DIABETOLOGIA, 1994, 37 (10) :985-993
[12]   HYPOTHALAMIC POLYPEPTIDE THAT INHIBITS SECRETION OF IMMUNOREACTIVE PITUITARY GROWTH-HORMONE [J].
BRAZEAU, P ;
VALE, W ;
BURGUS, R ;
LING, N ;
BUTCHER, M ;
RIVIER, J ;
GUILLEMIN, R .
SCIENCE, 1973, 179 (4068) :77-79
[13]   GLUCAGON IMMUNOREACTIVITY AND ANTI-DIABETIC ACTION OF SOMATOSTATIN IN THE TOTALLY DUODENO-PANCREATECTOMIZED AND GASTRECTOMIZED HUMAN [J].
BRINGER, J ;
MIROUZE, J ;
MARCHAL, G ;
PHAM, TC ;
LUYCKX, A ;
LEFEBVRE, P ;
ORSETTI, A .
DIABETES, 1981, 30 (10) :851-856
[14]   THE AMINO ACID SEQUENCE OF GLUCAGON [J].
BROMER, WW ;
SINN, LG ;
STAUB, A ;
BEHRENS, OK .
DIABETES, 1957, 6 (03) :234-238
[15]   A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance [J].
Bruning, JC ;
Michael, MD ;
Winnay, JN ;
Hayashi, T ;
Horsch, D ;
Accili, D ;
Goodyear, LJ ;
Kahn, CR .
MOLECULAR CELL, 1998, 2 (05) :559-569
[16]  
Buse JB., 2002, Clin Diabetes, V20, P137, DOI DOI 10.2337/DIACLIN.20.3.137
[17]   The unique cytoarchitecture of human pancreatic islets has implications for islet cell function [J].
Cabrera, O ;
Berman, DM ;
Kenyon, NS ;
Ricordi, C ;
Berggrern, PO ;
Caicedo, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2334-2339
[18]   Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor [J].
Cascieri, MA ;
Koch, GE ;
Ber, E ;
Sadowski, SJ ;
Louizides, D ;
de Laszlo, SE ;
Hacker, C ;
Hagmann, WK ;
MacCoss, M ;
Chicchi, GG ;
Vicario, PP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (13) :8694-8697
[19]   Evidence for a catabolic role of glucagon during an amino acid load [J].
Charlton, MR ;
Adey, DB ;
Nair, KS .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (01) :90-99
[20]   Use of GLUT-4 null mice to study skeletal muscle glucose uptake [J].
Charron, MJ ;
Gorovits, N ;
Laidlaw, JS ;
Ranalletta, M ;
Katz, EB .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2005, 32 (04) :308-313